Content Type: Commentary & Opinion

The Current 21st Century Cures Legislation Is Still A Bad Deal for Patients

March 16, 2026

The Daraprim Price Hike and A Role for Antitrust

March 16, 2026

Reference Check: A Simple Strategy to Improve Drug Patent Quality

March 16, 2026

Four Ways to Address the Ethical Tensions Around Expedited Approval of New Prescription Drugs

March 16, 2026

To Spur Medical Innovation, Make Corporate Cheaters Pay

March 16, 2026

Expanding Coercive Treatment Is the Wrong Solution for the Opioid Crisis

March 16, 2026

What Do High Drug Prices Buy Us?

March 16, 2026

President Biden Already Has the COVID Vaccine Recipe. He Should Share It

March 16, 2026

Biosimilar Approvals and the BPCIA: Too Soon to Give Up

March 16, 2026

Drugs Don’t Work If People Can’t Afford Them: The High Price of Tisagenlecleucel

March 16, 2026

The Pharmaceutical Market’s Adverse Effects

March 16, 2026

Challenging Patents to Promote Timely Generic Drug Entry: The Second Look Act and Other Options

March 16, 2026